(NASDAQ: CGC) Canopy Growth's forecast annual revenue growth rate of 7.6% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.41%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.37%.
Canopy Growth's revenue in 2025 is $192,188,888.On average, 3 Wall Street analysts forecast CGC's revenue for 2026 to be $30,445,472,371, with the lowest CGC revenue forecast at $30,046,335,572, and the highest CGC revenue forecast at $31,085,003,394. On average, 1 Wall Street analysts forecast CGC's revenue for 2027 to be $32,615,052,309, with the lowest CGC revenue forecast at $32,615,052,309, and the highest CGC revenue forecast at $32,615,052,309.
In 2028, CGC is forecast to generate $35,323,533,129 in revenue, with the lowest revenue forecast at $35,323,533,129 and the highest revenue forecast at $35,323,533,129.